Impact of 17-alpha-hydroxyprogesterone caproate on cytochrome P450s in primary cultures of human hepatocytes

American Journal of Obstetrics and Gynecology

Volumn 211, Issue 4, 2014, Pages 412.e1-412.e6

  Zhao, Yang ^a,d   Alshabi, Ali Mohamed ^a   Caritis, Steve ^c,d   Venkataramanan, Raman ^a,b,d,e,f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

Author keywords

17 alpha hydroxyprogesterone caproate; drug drug interaction; metabolism; primary cultures of human hepatocytes

Indexed keywords

17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; BIOLOGICAL MARKER; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 2C19; GESTAGEN; PROGESTERONE DERIVATIVE;

CELL CULTURE; DRUG EFFECTS; DRUG INTERACTION; EVALUATION STUDY; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CELL; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

BIOMARKERS; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; HYDROXYPROGESTERONES; PROGESTINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

EID: 84907708938     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2014.03.048     Document Type: Article

References (28)

1. P.J. Meis, M. Klebanoff, and E. Thom Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate N Engl J Med 348 2003 2379 2385
2. E.D. Deeks 17 alpha-Hydroxyprogesterone caproate (Makena): in the prevention of preterm birth Paediatr Drugs 13 2011 337 345
3. S.N. Caritis, S. Sharma, and R. Venkataramanan Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation Am J Obstet Gynecol 205 2011 40.e1 40.e8
4. S.N. Caritis, S. Sharma, and R. Venkataramanan Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation Am J Obstet Gynecol 207 2012 398.e1 398.e8
5. S. Sharma, J. Ou, S. Strom, D. Mattison, S. Caritis, and R. Venkataramanan Identification of enzymes involved in the metabolism of 17alpha-hydroxyprogesterone caproate: an effective agent for prevention of preterm birth Drug Metab Dispos 36 2008 1896 1902
6. S. Sharma, E.C. Ellis, and K. Dorko Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes Drug Metab Dispos 38 2010 723 727
7. R. Yan, T.N. Nanovskaya, O.L. Zharikova, D.R. Mattison, G.D. Hankins, and M.S. Ahmed Metabolism of 17alpha-hydroxyprogesterone caproate by hepatic and placental microsomes of human and baboons Biochem Pharmacol 75 2008 1848 1857
8. Federal Drug Administration. Center for Drug Evaluation and Research. Approval letter for hydroxyprogesterone caproate injection. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/021945Orig1s000Approv.pdf. Accessed Dec. 19, 2013.
9. Federal Drug Administration. Center for Drug Evaluation and Research. Summary review for hydroxyprogesterone caproate injection. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/021945Orig1s000SumR.pdf. Accessed Dec. 19, 2013.
10. W.F. Rayburn, and J.P. Lavin Jr. Drug prescribing for chronic medical disorders during pregnancy: an overview Am J Obstet Gynecol 155 1986 565 569
11. V. Chu, H.J. Einolf, and R. Evers In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations; a Pharmaceutical Research and Manufacturers of America perspective Drug Metab Dispos 37 2009 1339 1354
12. T.D. Bjornsson, J.T. Callaghan, and H.J. Einolf The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab Dispos 31 2003 815 832
13. V.C. Pillai, S.C. Strom, S.N. Caritis, and R. Venkataramanan A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS J Pharm Biomed Anal 74 2013 126 132
14. S. Fleige, V. Walf, S. Huch, C. Prgomet, J. Sehm, and M.W. Pfaffl Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR Biotechnol Lett 28 2006 1601 1613
15. A.A. Mitchell, S.M. Gilboa, and M.M. Werler Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008 Am J Obstet Gynecol 205 2011 51.e1 51.e8
16. S.E. Andrade, J.H. Gurwitz, and R.L. Davis Prescription drug use in pregnancy Am J Obstet Gynecol 191 2004 398 407
17. M.T. Donato, and J.V. Castell Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies Clin Pharmacokinet 42 2003 153 178
18. R.L. Walsky, and R.S. Obach Validated assays for human cytochrome P450 activities Drug Metab Dispos 32 2004 647 660
19. R.D. Pelletier, W.G. Lai, and Y.N. Wong Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes J Biomol Screen 18 2013 199 210
20. A. Hashemi, F. Roohvand, and M.H. Ghahremani Selection of valid reference genes for expression studies of hepatic cell lines under IFN-alpha treatment Biochem Biophys Res Commun 426 2012 649 653
21. R.D. Barber, D.W. Harmer, R.A. Coleman, and B.J. Clark GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues Physiol Genomics 21 2005 389 395
22. I.V. Tetko, J. Gasteiger, and R. Todeschini Virtual computational chemistry laboratory-design and description J Comput Aided Mol Des 19 2005 453 463
23. V.A. Payne, Y.T. Chang, and G.H. Loew Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes Proteins 37 1999 204 217
24. A. Rebarber, N. Fox, C.K. Klauser, D. Saltzman, and A.S. Roman A national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval Clin Drug Investig 33 2013 571 577
25. A.W. Cohen, J.A. Copel, G.A. Macones, M.K. Menard, L. Riley, and G.R. Saade Unjustified increase in cost of care resulting from US Food and Drug Administration approval of Makena (17alpha-hydroxyprogesterone caproate) Obstet Gynecol 117 2011 1408 1412
26. U.M. Zanger, and M. Schwab Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther 138 2013 103 141
27. S.A. Ward, N.A. Helsby, E. Skjelbo, K. Brosen, L.F. Gram, and A.M. Breckenridge The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study Br J Clin Pharmacol 31 1991 689 692
28. R. McGready, K. Stepniewska, and M.D. Edstein The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria Eur J Clin Pharmacol 59 2003 545 552